Medical Doctor Program year 2024 Reported 2020–2024 Source: CMS Open Payments, 2026 publication

Judy Lin

Emergency Medicine Washington, DC Medical Doctor

NPI 1467771204 CMS profile 575838

110 Irving St Nw, Washington, DC 20010

Open in the dashboard

General payments

$8,307

10 records reported · program years 2020–2024

Research payments

$0

Paid to them · None reported · program years 2020–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Judy Lin of Washington, DC is reported in the CMS Open Payments database as having received $8,307 across 10 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $3,550 2
2022 General $18 1
2021 General $4,673 6
2020 General $65 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Judy Lin
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Judy Lin were reported at $0. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Judy Lin Emergency Medicine median Middle half National median
2019 $0 $51 $18–$128 $163
2020 $65 $29 $16–$99 $114
2021 $4,673 $40 $18–$124 $132
2022 $18 $49 $20–$134 $149
2023 $0 $51 $22–$142 $160
2024 $3,550 $52 $22–$150 $164
2025 $0 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2020–2024
  1. Pacira Pharmaceuticals Incorporated $4,668 4 payments
  2. Exo Imaging, Inc. $3,550 2 payments
  3. AstraZeneca Pharmaceuticals LP $71 3 payments
  4. CSL Behring $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2024
  1. Consulting Fee $4,480 1 payment
  2. Long term medical supply or device loan $3,500 1 payment
  3. Food and Beverage $219 6 payments
  4. Travel and Lodging $57 1 payment
  5. Gift $50 1 payment
Products named General payments · program years 2020–2024
  1. Exparel $4,602 3 payments
  2. Exo Iris $3,550 2 payments
  3. LOKELMA $71 3 payments
  4. iovera System $65 1 payment
  5. Kcentra $18 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

51

Median for Emergency Medicine: 88

Drug cost

$539

Median for Emergency Medicine: $590

Branded share of claims

72.5%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cefuroxime Cefuroxime Axetil Brand 22 $393
Methocarbamol Generic 14 $97
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 15 $49

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$31,813

Medicare's payments for the services billed

Medicare patients

200

Average age 73

Services billed

338

114 women, 86 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 57%
Arthritis 57%
Diabetes 55%
Depression 47%
Heart failure 44%
Ischemic heart disease 44%
Atrial fibrillation 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record